Merck’s Lab Closure Harms Japan’s Drug-Making Goals – Japanese Cabinet Official
This article was originally published in PharmAsia News
Executive Summary
A Japanese official said U.S.-based Merck's decision to close its research laboratory in Japan is a blow to the government's effort to make the country one of the world's largest drug makers. Merck, Pfizer, Novartis AG and GlaxoSmithKline have closed labs recently, in most cases moving them to other Asian nations. Kiyoshi Kurokawa, the Cabinet's policy adviser, said the government plan to double drug production and attract foreign makers will be hampered by the closings. Japan's goal is to be developer of a quarter of the world's new drugs. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.